@article{fdi:010078032,
  title = {{D}ifferences in {HIV} cure clinical trial preferences of {F}rench people living with {HIV} and physicians in the {ANRS}-{APSEC} study : a discrete choice experiment},
  author = {{P}rotiere, {C}. and {A}rnold, {M}. and {F}iorentino, {M}arion and {F}ressard, {L}. and {L}elievre, {J}. {D}. and {M}imi, {M}. and {R}affi, {F}. and {M}ora, {M}. and {M}eyer, {L}. and {S}agaon {T}eyssier, {L}uis and {Z}ucman, {D}. and {P}reau, {M}. and {L}ambotte, {O}. and {S}pire, {B}. and {S}uzan-{M}onti, {M}. and {ANRS}-{APSEC} {S}tudy {G}roup},
  editor = {},
  language = {{ENG}},
  abstract = {{I}ntroduction {D}espite the advent of {HIV} cure-related clinical trials ({HCRCT}) for people living with {HIV} ({PLWH}), the risks and uncertainty involved raise ethical issues. {A}lthough research has provided insights into the levers and barriers to {PLWH} and physicians' participation in these trials, no information exists about stakeholders' preferences for {HCRCT} attributes, about the different ways {PLWH} and physicians value future {HCRCT}, or about how personal characteristics affect these preferences. {T}he results from the present study will inform researchers' decisions about the most suitable {HCRCT} strategies to implement, and help them ensure ethical recruitment and well-designed informed consent. {M}ethods {B}etween {O}ctober 2016 and {M}arch 2017, a discrete choice experiment was conducted among 195 virally controlled {PLWH} and 160 physicians from 24 {F}rench {HIV} centres. {P}rofiles within each group, based on individual characteristics, were obtained using hierarchical clustering. {T}rade-offs between five {HCRCT} attributes (trial duration, consultation frequency, moderate (digestive disorders, flu-type syndrome, fatigue) and severe (allergy, infections, risk of cancer) side effects ({SE}), outcomes) and utilities associated with four {HCRCT} candidates (latency reactivation, immunotherapy, gene therapy and a combination of latency reactivation and immunotherapy), were estimated using a mixed logit model. {R}esults {A}part from severe {SE} - the most decisive attribute in both groups - {PLWH} and physicians made different trade-offs between {HCRCT} attributes, the latter being more concerned about outcomes, the former about the burden of participation (consultation frequency and moderate {SE}). {T}hese different trades-offs resulted in differences in preferences regarding the four candidate {HCRCT}. {PLWH} significantly preferred immunotherapy, whereas physicians preferred immunotherapy and combined therapy. {D}espite the heterogeneity of characteristics within the {PLWH} and physician profiles, results show some homogeneity in trade-offs and utilities regarding {HCRCT}. {C}onclusions {S}evere {SE}, not outcomes, was the most decisive attribute determining future {HCRCT} participation. {P}articular attention should be paid to providing clear information, in particular on severe {SE}, to potential participants. {I}mmunotherapy would appear to be the best {HCRCT} candidate for both {PLWH} and physicians. {H}owever, if the risk of cancer could be avoided, gene therapy would become the preferred strategy for the latter and the second choice for the former.},
  keywords = {{HIV} eradication ; remission ; therapeutic {HIV} vaccine trial ; social sciences ; discrete choice experiment ; preferences ; ethics ; clinical ; trial design recommendations ; mixed logit model ; {FRANCE}},
  booktitle = {},
  journal = {{J}ournal of the {I}nternational {A}ids {S}ociety},
  volume = {23},
  numero = {2},
  pages = {e25443},
  year = {2020},
  DOI = {10.1002/jia2.25443},
  URL = {https://www.documentation.ird.fr/hor/fdi:010078032},
}